newsfilter
← Latest News
GlobeNewswire·

NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

Updated Phase 1b dataset provides nearly 18 months of median follow-up and shows the durability of clinical benefit observed with givastomigClinical activity observed across CLDN18.2 expression levels, including in